GlobeNewswire Inc | Nov 24, 2021 01:30AM EST

November 24, 2021

Montrouge, France, November 24, 2021

DBV Technologies to Participate in an Upcoming Investor Conference

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 4th Annual Evercore ISI HealthCONx Conference. Daniel Tass, Chief Executive Officer, will participate in a fireside chat on Wednesday, December 1st at 8am ET.

A live webcast of the fireside chat will be available on the Investors & Media sectionof the Companys website: https://www.dbv-technologies.com/investor-relations.

A replay will also be available on DBV Technologies website after the event.

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com

Media ContactAngela MarcucciDBV Technologies+1646-842-2393angela.marcucci@dbv-technologies.com

Attachment

-- version PDF